ReShape Lifesciences Inc. (OTCMKTS:RSLS – Get Rating) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.63 and traded as high as $4.47. ReShape Lifesciences shares last traded at $4.01, with a volume of 114,460 shares traded.
ReShape Lifesciences Trading Down 10.3 %
The business’s 50 day simple moving average is $6.71 and its 200 day simple moving average is $2.63. The firm has a market capitalization of $2.09 million, a PE ratio of -0.02 and a beta of 0.02.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ReShape Lifesciences stock. Renaissance Technologies LLC purchased a new stake in ReShape Lifesciences Inc. (OTCMKTS:RSLS – Get Rating) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 44,697 shares of the medical device company’s stock, valued at approximately $26,000. Renaissance Technologies LLC owned about 0.24% of ReShape Lifesciences as of its most recent filing with the Securities & Exchange Commission. 3.29% of the stock is currently owned by institutional investors and hedge funds.
About ReShape Lifesciences
ReShape Lifesciences, Inc is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.
- Get a free copy of the StockNews.com research report on ReShape Lifesciences (RSLS)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.